Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Slides:

Advertisements

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Advertisements

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity Andrei Malinovschi,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Risk of an asthma exacerbation after bariatric surgery in adults

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study Karoline Krause, MD, Athanasios Tsianakas,

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Oral steroids and doxycycline: Two different approaches to treat nasal polyps Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

T-cell regulation in chronic paranasal sinus disease

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Airway and serum biochemical correlates of refractory neutrophilic asthma Rafeul Alam, MD, PhD, James Good, MD, Donald Rollins, MD, Mukesh Verma, PhD,

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

The quest for autoreactive antibodies in nasal polyps

TGF-β signaling and collagen deposition in chronic rhinosinusitis

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Jon Genuneit, MD, MSc Journal of Allergy and Clinical Immunology

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Early decreases in blood eosinophil levels with reslizumab

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease Nan Zhang, MD, PhD, Thibaut Van Zele, MD, PhD, Claudina.

Matthew J. Loza, PhD, Susan Foster, PhD, Stephen P

Paul V. Licciardi, PhD, Anne Balloch, MSc, Fiona M

Claus Bachert, MD, PhD, Luo Zhang, MD, Phillippe Gevaert, MD

Biology of nasal polyposis

Martin Brasholt, MD, Florent Baty, PhD, Hans Bisgaard, MD, DMSci

Xiu-Min Li, MD, LaVerne Brown, PhD

Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti–IL-5 antibody SCH55700 Yae-Jean.

Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis Iris M. Otani, MD, Arjun A. Anilkumar,

Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps Joke Patou, MD, Philippe Gevaert, MD, PhD, Thibaut.

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

Nasal challenge with allergen leads to maxillary sinus inflammation

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Macrolide antibiotics and asthma treatment

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Albert Y. Wu, MD, Sanjiv Sur, MD, J. Andrew Grant, MD

Charcot-Leyden crystal concentration in nasal secretions predicts clinical response to glucocorticoids in patients with chronic rhinosinusitis with nasal.

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

Environmental factors and eosinophilic esophagitis

Systemic responses after bronchial aspirin challenge in sensitive patients with asthma Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies Frank C. Albers, MD, PhD, Robert G. Price,

Presentation transcript:

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert, PhD, Kristel Van Steen, PhD, Thibaut Van Zele, MD, PhD, Frederic Acke, MD, Natalie De Ruyck, MSc, Katrien Blomme, MSc, Ana R. Sousa, PhD, Richard P. Marshall, MD, PhD, Claus Bachert, MD, PhD Journal of Allergy and Clinical Immunology Volume 128, Issue 5, Pages 989-995.e8 (November 2011) DOI: 10.1016/j.jaci.2011.07.056 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 A, Mean CFB in TPS based on LOCF for the treated (solid line) and placebo (dashed line) groups starting at the moment of first administration. Error bars indicate 95% CIs of the mean based on normal approximation. B, Baseline and week 8 TPSs in absolute values based on LOCF for each subject and divided into the mepolizumab-treated and placebo groups. Journal of Allergy and Clinical Immunology 2011 128, 989-995.e8DOI: (10.1016/j.jaci.2011.07.056) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Mean CFB in serum ECP levels, blood eosinophil counts, serum IL-5Rα levels, and nasal MPO levels and mean nasal IL-1β and IL-5Rα levels (all in micrograms per liter), imputing 0 for observations of less than the LDL. These representations are based on LOCF and show the mepolizumab-treated (solid line) and placebo (dashed line) groups starting at the moment of first administration. Error bars indicate 95% CIs of the mean based on normal approximation. Journal of Allergy and Clinical Immunology 2011 128, 989-995.e8DOI: (10.1016/j.jaci.2011.07.056) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Proportion of patients still in the study in the mepolizumab-treated (solid line) and placebo (dashed line) groups starting at the moment of first administration. Journal of Allergy and Clinical Immunology 2011 128, 989-995.e8DOI: (10.1016/j.jaci.2011.07.056) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Study outline showing the different patient visits and the respective investigations. Journal of Allergy and Clinical Immunology 2011 128, 989-995.e8DOI: (10.1016/j.jaci.2011.07.056) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 Proportional improvement in CT scan scores based on LOCF for the mepolizumab-treated (black columns) and placebo (gray columns) groups rated by 3 different observers (A, B, and C). Error bars indicate 95% CIs of the proportion based on normal approximation. Journal of Allergy and Clinical Immunology 2011 128, 989-995.e8DOI: (10.1016/j.jaci.2011.07.056) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 Mean CFB in nPIF based on LOCF for the treated (solid line) and placebo (dashed line) groups starting at the moment of first administration. Journal of Allergy and Clinical Immunology 2011 128, 989-995.e8DOI: (10.1016/j.jaci.2011.07.056) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E4 Individual values of serum ECP levels, blood eosinophil counts, serum IL-5Rα levels, and nasal MPO levels (all in micrograms per liter) at weeks 0 and 8 based on LOCF for the mepolizumab-treated and placebo groups. Journal of Allergy and Clinical Immunology 2011 128, 989-995.e8DOI: (10.1016/j.jaci.2011.07.056) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E5 Mean CFB in TPS based on LOCF for responders (solid line) and nonresponders (dashed line) starting at the moment of first administration. Error bars indicate 95% CIs of the mean based on normal approximation. Journal of Allergy and Clinical Immunology 2011 128, 989-995.e8DOI: (10.1016/j.jaci.2011.07.056) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions